Mark Till
Impact in
- Biotechnology top 1%
- Transgenic Plants and Applications
- Immunology top 5%
- Toxin Mechanisms and Immunotoxins
- Immune Cell Function and Interaction
Papers in
- Immunology 11
- Toxin Mechanisms and Immunotoxins 10
- Galectins and Cancer Biology 3
- Immunotherapy and Immune Responses 1
-
- Transgenic Plants and Applications 8
- Co-authors
- Richard May (8 shared papers)Ellen S. Vitetta (7 shared papers)Jonathan W. Uhr (6 shared papers)R J Fulton (2 shared papers)Victor Gheţie (7 shared papers)P L Amlot (3 shared papers)E S Vitetta (1 shared paper)Marvin J. Stone (1 shared paper)
- Journals
- Science (2 papers)International Journal of Cancer (1 paper)Cellular Immunology (1 paper)Bioconjugate Chemistry (1 paper)Journal of Immunological Methods (1 paper)
- Partner nations
- United StatesUnited Kingdom
In The Last Decade
Mark Till
12 papers receiving 929 citations
Peers
Comparison fields: 5 of 65
- Biotechnology 455
- Immunology 747
- Virology 98
- Radiology, Nuclear Medicine and Imaging 385
- Toxicology 20
Countries citing papers authored by Mark Till
This map shows the geographic impact of Mark Till's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Till with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Till more than expected).
Fields of papers citing papers by Mark Till
This network shows the impact of papers produced by Mark Till. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Till. The network helps show where Mark Till may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Till, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1987 | 281 | |
| 2 | Phase I immunotoxin trial in patients with B-cell lymphoma. | 1991 | 242 |
| 3 | 1988 | 123 | |
| 4 | Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. | 1988 | 107 |
| 5 | 1988 | 64 | |
| 6 | 1989 | 53 | |
| 7 | An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins. | 1988 | 39 |
| 8 | 1989 | 32 | |
| 9 | 1990 | 20 | |
| 10 | Immunoconjugates containing ricin A chain and either human anti-gp41 or CD4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell function. | 1990 | 18 |
| 11 | 1990 | 9 | |
| 12 | Monoclonal antibodies as carriers of toxins. | 1989 | 3 |
About Mark Till
Mark Till is a scholar working on Immunology, Biotechnology, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Neurology, having authored 12 papers that have together received 991 indexed citations. Recurring topics across this work include Toxin Mechanisms and Immunotoxins (10 papers), Transgenic Plants and Applications (8 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Galectins and Cancer Biology (3 papers), Glycosylation and Glycoproteins Research (2 papers), Plant tissue culture and regeneration (2 papers), Herpesvirus Infections and Treatments (1 paper) and Immunotherapy and Immune Responses (1 paper). The work is most often cited by research in Biotechnology (455 citations), Immunology (747 citations), Virology (98 citations), Radiology, Nuclear Medicine and Imaging (385 citations) and Toxicology (20 citations). Mark Till has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Richard May, Ellen S. Vitetta, Jonathan W. Uhr, R J Fulton, Victor Gheţie, P L Amlot, E S Vitetta, Marvin J. Stone, JW Fay and P. Clark. Their work appears in journals such as Science, International Journal of Cancer, Cellular Immunology, Bioconjugate Chemistry and Journal of Immunological Methods.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.